DPP4

DPP4

A gene on chromosome 2q24.3 that encodes dipeptidyl-peptidase 4, a ubiquitous, membrane-bound enzyme with roles in nutrition, metabolism, the endocrine system, immune regulation (for instance, it is essential for T-cell receptor (TCR)-mediated T-cell activation), bone marrow mobilisation, apoptosis, cell adhesion and tumourigenesis.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
DPP4 may also affect cardiovascular function through regulation of inflammation.
If we are able to predict the renoprotective effect of a DPP4 inhibitor by some biomarkers before the treatment, this has a clinical impact and a possibility to reduce the medical costs on patients with T2D.
Su, "DPP4 deficiency preserved cardiac function in abdominal aortic banding rats," PLoS ONE, vol.
Additionally, when measuring "active" GLP-1, it is advised to use a DPP4 inhibitor when collecting blood samples [12].
Among patients treated with oral hypoglycemic drugs, metformin was used by 61.5%, sulphonylureas by 33%, repaglinide by 9.3%, and a combination of metformin and glibenclamide by 4.8%; the remaining patients were treated with metformin and pioglitazone (0.8%), acarbose (0.8%), and metformin and DPP4 inhibitors (0.6%).
The inhibitors of DPP4, or gliptins, stabilize GLP-1 levels by inhibiting its degradation and lower fasting and postprandial glucose.
These amino acid changes are located outside the binding interface between MERS-CoV spike protein and human DPP4 receptor, suggesting these amino acid differences are unlikely to affect receptor binding.
have demonstrated that increased DPP-4 activity, evoked by angiotensin II, suppresses megalin expression in mice, an effect that was partially abolished by using a DPP4 inhibitor [153].
The participants with type 2 diabetes who visited the outpatient clinic of diabetes at Kawasaki Medical School Hospital and had dipeptidyl peptidase-4 (DPP4) inhibitors, that is, sitagliptin 50 mg/day, vildagliptin 100 mg/day, and alogliptin 25 mg/day, for over 1 year were eligible in this study.
Following the discovery that the insulinotropic effect of GLP-1 is preserved in most patients with T2DM [89], GLP-1 mimetics and inhibitors of GLP-1 degradation by dipeptidyl peptidase 4 (DPP4) have been developed and licensed for the treatment of T2DM [90].
Glucose-lowering therapy such as GLP-1 agonists, DPP4 inhibitors, and SGLT2 inhibitors is reported to improve renal function in type 2 diabetes patients.
Infection of Huh-7 cells could also be blocked by preincubation of cells with polyclonal antiserum against human DPP4 but not with control serum (Figure 2, panel A).